Press release
Leptomeningeal Metastases Market Size in 7MM was ~USD 1700 Million in 2024 and which is expected to rise in 2034, estimates DelveInsight
Leptomeningeal Metastases Market Size
Discover Key Insights into the Leptomeningeal Metastases Market with DelveInsight's In-Depth Report @ Leptomeningeal Metastases Treatment Market Size- https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Leptomeningeal Metastases Market Report
• On 17 October 2025, Standford University conducted a study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic cancer with CNS involvement.
• On 14 October 2025, Nantong Bencao Quadriga Medical Technology Co. Ltd. announced a phase IIa study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.
• In 2024, the total Leptomeningeal Metastases Incident Cases were approximately 120,000 in the US, reflecting its significant disease burden and the pressing need for improved diagnostic tools and more effective treatments.
• In 2024, breast cancer recorded the highest incident cases of leptomeningeal metastases among all cancer types across EU4 and the UK, with approximately 30,000 cases reported.
• In Germany in 2024, incident leptomeningeal metastases cases were stratified by risk classification, with 66% of patients falling under the "good risk" category and the remaining 34% categorized as "poor risk." This distribution highlights a predominance of favorable prognostic profiles within the affected population.
• The leading Leptomeningeal Metastases Companies such as Plus Therapeutics, Kazia Therapeutics, Genentech and others.
• Promising Leptomeningeal Metastases Therapies such as Bevacizumab, Nivolumab, Ipilimumab, Pertuzumab, Trastuzumab, Tesevatinib, TY-9591 Tablets, Trastuzumab deruxtecan, and others.
Stay ahead in the Leptomeningeal Metastases Therapeutics Market with DelveInsight's Strategic Report @ Leptomeningeal Metastases Market Outlook- https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Leptomeningeal Metastases Epidemiology Segmentation in the 7MM
• Total Leptomeningeal Metastases Incident Cases
• Leptomeningeal Metastases Incident Cases by Cancer Type
• Leptomeningeal Metastases Incident Cases by Risk Type
• Leptomeningeal Metastases Gender-specific Cases
• Leptomeningeal Metastases Treated Patient Pool
Download the report to understand which factors are driving Leptomeningeal Metastases epidemiology trends @ Leptomeningeal Metastases Prevalence- https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Leptomeningeal Metastases Emerging Therapies
• REYOBIQ (rhenium Re186 obisbemeda): Plus Therapeutics
REYOBIQ (rhenium Re186 obisbemeda) is an innovative injectable radiotherapy designed to deliver high-dose, targeted radiation directly to central nervous system tumors with a focus on safety, efficacy, and ease of administration. Leveraging the unique properties of rhenium-186, its short half-life, beta emissions for tumor destruction, and gamma emissions for real-time imaging REYOBIQ offers a promising approach for CNS therapies. It is currently under evaluation for the Leptomeningeal Metastases Treatment in the ongoing ReSPECT-LM clinical trials.
• Paxalisib: Kazia Therapeutics/Genentech
Paxalisib (GDC-0084) is an experimental therapy under development for treating a range of brain cancers. It acts as a brain-penetrant inhibitor of the PI3K/Akt/mTOR signaling pathway, which plays a vital role in regulating cell growth and division. What sets paxalisib apart from other agents in its class is its design tailored to cross the blood-brain barrier enabling efficient drug delivery to brain tissue, a critical advantage in targeting central nervous system malignancies.
Leptomeningeal Metastases Drug Analysis
The section dedicated to drugs in the leptomeningeal metastases treatment market report provides an in-depth evaluation of late-stage pipeline drugs related to leptomeningeal metastases. The drug chapters section provides valuable information on various aspects related to leptomeningeal metastases clinical trials, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting leptomeningeal metastases.
Get In-Depth Knowledge on Leptomeningeal Metastases Market Trends and Forecasts with DelveInsight @ Leptomeningeal Metastases Therapeutics Market Size- https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Leptomeningeal Metastases Companies
Plus Therapeutics, Kazia Therapeutics, Genentech and others.
Scope of the Leptomeningeal Metastases Market Report
• Coverage- 7MM
• Forecast Period- 2025-2034
• Leptomeningeal Metastases Companies- Plus Therapeutics, Kazia Therapeutics, Genentech and others.
• Leptomeningeal Metastases Therapies- Bevacizumab, Nivolumab, Ipilimumab, Pertuzumab, Trastuzumab, Tesevatinib, TY-9591 Tablets, Trastuzumab deruxtecan, and others.
• Leptomeningeal Metastases Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Leptomeningeal Metastases Unmet Needs, KOL's views, Analyst's views, Leptomeningeal Metastases Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight's Comprehensive Leptomeningeal Metastases Market Report @ Leptomeningeal Metastases Market Drivers and Barriers- https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Contents
1. Key Insights
2. Report Introduction
3. Leptomeningeal Metastases Market Overview at a Glance
4. Epidemiology and Market Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Treatment and Management
9. Epidemiology and Patient Population
10. Patient Journey
11. Emerging Therapies
12. Leptomeningeal Metastases - Seven Major Market Analysis
13. KOL Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leptomeningeal Metastases Market Size in 7MM was ~USD 1700 Million in 2024 and which is expected to rise in 2034, estimates DelveInsight here
News-ID: 4242675 • Views: …
More Releases from DelveInsight Business Research LLP
Chronic Lower Back Pain Market Projected to Grow by 2034
Chronic Lower Back Pain Market Projected to Grow by 2034 | Eli Lilly, Collegium Pharmaceutical, Purdue Pharma, BioDelivery Sciences, Camurus, Braeburn, Scilex Holding, Mesoblast, AnGes MG, Kolon Life Science, Eliem Therapeutics, Allodynic Therapeutics, Sollis Therapeutics, Medtronic Spinal & Biologics, Frontier Biotechnologies, DiscGenics, Pfizer, Persica Pharmaceuticals, BioRestorative Therapies, Vertanical GmbH, Stayble Therapeutics, and SpineThera Expected to Lead Market Expansion
The growth of the chronic lower back pain market is driven by rising…
Chronic Obstructive Pulmonary Disease (COPD) Market Projected to Grow by 2034
Chronic Obstructive Pulmonary Disease (COPD) Market Projected to Grow by 2034 | AstraZeneca/Circassia, GlaxoSmithKline/Theravance/Innoviva, Chiesi Farmaceutici, Sunovion, Boehringer Ingelheim, Sanofi/Regeneron, United Therapeutics, Verona Pharma, Inmunotek, Novartis, Organicell Regenerative Medicine, Vertex, Pulmotect, Genentech, Mereo BioPharma, Biomarck Pharmaceuticals Expected to Lead Market Expansion
The growth of the chronic obstructive pulmonary disease (COPD) market is driven by factors such as rising disease prevalence, increased investments in research and development, and the introduction of innovative…
Periodontal Disease market is projected to experience significant growth by 2032
Periodontal Disease market is projected to experience significant growth by 2032, driven by major players such as Dentsply Sirona Inc., Envista Holdings Corporation, A-dec Inc., J. Morita Corp., Straumann Group, BIOLASE, BEGO GmbH & Co. KG, Ultradent Products, and Yoshida Dental.
Key factors contributing to this growth include the rising prevalence of Periodontal Disease, increased investments in R&D, and the introduction of novel and emerging therapies during the forecast period 2019-2032.
Additionally,…
Myeloproliferative Disorder Treatment Market Size Report 2032 | Novartis AG, Inc …
DelveInsight's Myeloproliferative Disorder Treatment Market Insights Report 2032 provides the current and forecast market analysis, individual leading Myeloproliferative Disorder Treatment Companies market shares, challenges, Myeloproliferative Disorder Treatment Market Drivers, barriers, trends, and key market Myeloproliferative Disorder Treatment companies in the market.
To read more about the latest highlights related to the Myeloproliferative Disorder Treatment Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/myeloproliferative-disorder-treatment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways…
More Releases for Leptomeningeal
Leptomeningeal Metastases Pipeline 2025: Therapies Under Investigation, Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Leptomeningeal Metastases pipeline constitutes 5+ key companies continuously working towards developing 5+ Leptomeningeal Metastases treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Leptomeningeal Metastases Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Leptomeningeal Metastases Market.
The Leptomeningeal…
Leptomeningeal Metastases Market Size, Share and Growth Report, 2034
Introduction
The Leptomeningeal Metastases (LM) market is gaining increased attention as survival rates for primary cancers improve, leading to higher detection of late-stage complications like LM. This rare but severe condition occurs when cancer cells spread to the leptomeninges and cerebrospinal fluid (CSF), most often from breast cancer, lung cancer, or melanoma. Historically associated with poor prognosis, LM treatment is evolving with advancements in molecular diagnostics, targeted therapies, intrathecal drug delivery…
Trailhead Biosystems® Develops iPSC-Derived Vascular Leptomeningeal Cells
Beachwood, Ohio, March 5, 2025 - Trailhead Biosystems, Inc. (trailbio.com), a biotechnology company pioneering the creation of iPSC-derived human cells at scale for drug discovery and cell therapy, proudly announces the launch of TrailBio® Vascular Leptomeningeal Cells. As the first of their kind on the market, these unique cells provide researchers with a new tool to directly study the blood-brain barrier's permeability and regulatory mechanisms. This advancement represents a significant…
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical …
Leptomeningeal Metastases companies are Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, and others.
(Albany, USA) DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Leptomeningeal Metastases…
Leptomeningeal Metastases Treatment Market 2034: EMA, PDMA, FDA Approvals, Clini …
Leptomeningeal Metastases companies working in the market are Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, Inc., and others.
(Albany, USA) DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United…
Leptomeningeal Metastases Treatment Market Size, Forecast, Drugs, and Companies …
Leptomeningeal Metastases Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Leptomeningeal Metastases Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Leptomeningeal Metastases, historical and…
